Edwards Lifesciences (EW) Q1 FY2022 earnings: revenue $1.3 billion, up 10.2% on the year

Edwards Lifesciences Corp. (EW) reported revenue of $1.3 billion for Q1 FY2022, the quarter ended 31 March 2022, up 10.2% on the same quarter a year earlier as this quarter's filing gives it. Net income was $374 million, up 10.5% on the year as this quarter's filing gives it, and diluted earnings per share $0.59. The figures are the company's own, from the 10-Q it filed with the SEC on 28 April 2022.

Revenue

$1.3 billion

+10.2% on the year · +0.9% on the quarter

Q2 FY2020Q1 FY2022

Operating margin

32.7%

31.5% a year earlier

Q2 FY2020Q1 FY2022

Net income

$374 million

+10.5% on the year · +11.4% on the quarter

Q2 FY2020Q1 FY2022

Diluted EPS

$0.59

+9.3% on the year · +11.3% on the quarter

Q2 FY2020Q1 FY2022

this quarterthe same quarter a year earlierHover a bar for its figure.

Income statement (profit and loss)

$ million	Q1 FY2022	Q4 FY2021	Q1 FY2021	On the quarter	On the year
Revenue	1,341	1,330	1,217	+0.9%	+10.2%
Cost of revenue	299	310	n/a	-3.3%
Gross profit	1,042	1,020	n/a	+2.1%
Gross margin	77.7%	76.7%	n/a
Research and development	229	233	n/a	-1.8%
Selling, general and administrative	370	424	n/a	-12.7%
Operating income	439	374	384	+17.2%	+14.4%
Operating margin	32.7%	28.2%	31.5%
Pre-tax income	436	376	n/a	+15.9%
Income tax	62.5	41.0	n/a	+52.4%
Effective tax rate	14.3%	10.9%	n/a
Net income	374	335	338	+11.4%	+10.5%
Net margin	27.9%	25.2%	n/a
Diluted EPS	$0.59	$0.53	$0.54	+11.3%	+9.3%

$ million except per share.

Fourth quarters are the year less the first three quarters. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow

$ million	Q1 FY2022	Q4 FY2021	Q1 FY2021	On the quarter	On the year
Operating cash flow	293	374	n/a	-21.5%
Capital expenditure	72.7	89.8	n/a	-19.0%
Free cash flow	221	284	n/a	-22.3%
Free cash flow margin	16.4%	21.3%	n/a
Cash from investing	230	-966	n/a
Cash from financing	-368	-62.0	n/a
Depreciation and amortisation	34.7	33.0	32.4	+5.2%	+7.1%
Share-based compensation	32.4	24.2	n/a	+33.9%
Buybacks	406	96.5	n/a	+320.3%
Diluted shares, weighted	629m	632m	631m	-0.4%	-0.3%
Shares outstanding at period end	621m	624m	622m	-0.4%	-0.1%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet

$ million	Q1 FY2022	Q4 FY2021	Q1 FY2021	On the quarter	On the year
Shareholders' equity	5,845	5,836	4,658	+0.2%	+25.5%
Debt	596	596	595	+0.0%	+0.1%
Operating lease liabilities	68.4	69.1	n/a	-1.0%
Other liabilities	1,911	2,002	n/a	-4.6%
Total liabilities and equity	8,420	8,503	n/a	-1.0%
Fixed assets	1,552	1,547	n/a	+0.4%
Goodwill	1,166	1,168	n/a	-0.1%
Intangible assets	322	324	n/a	-0.5%
Investments	2,089	2,438	n/a	-14.3%
Cash and equivalents	1,031	863	1,174	+19.5%	-12.2%
Receivables	636	582	n/a	+9.3%
Inventory	731	727	n/a	+0.5%
Other assets	893	855	n/a	+4.5%
Total assets	8,420	8,503	n/a	-1.0%

Questions

What was Edwards Lifesciences' revenue in Q1 FY2022?

Edwards Lifesciences (EW) reported revenue of $1.3 billion for Q1 FY2022, the quarter ended 31 March 2022, up 10.2% on the same quarter a year earlier as the company restated it.

How much did Edwards Lifesciences earn in Q1 FY2022?

Net income for Q1 FY2022 was $374 million, up 10.5% on the year, and diluted earnings per share $0.59.

When did Edwards Lifesciences report Q1 FY2022 results?

Edwards Lifesciences filed its 10-Q for the quarter ended 31 March 2022 with the SEC on 28 April 2022.

Quarterly results, the last 20 quarters

	Q4 FY2021 *	Q1 FY2022	Q2 FY2022	Q3 FY2022	Q4 FY2022 *	Q1 FY2023 †	Q2 FY2023 †	Q3 FY2023 †	Q4 FY2023	Q1 FY2024 †	Q2 FY2024 †	Q3 FY2024	Q4 FY2024 †	Q1 FY2025	Q2 FY2025	Q3 FY2025	Q4 FY2025 *	Q1 FY2026	Q2 FY2026	Q3 FY2026
Revenue	1,330	1,341	1,374	1,319	1,348	1,221	1,279	1,243	1,266	1,330	1,369	1,354	1,386	1,413	1,532	1,553	1,570	1,649	1,741	1,716
Cost of revenue	310	299	269	254	258	330	257	251	357	287	276	263	292	302	344	345	343	363	392	369
Gross profit	1,020	1,042	1,104	1,065	1,090	992	1,031	993	1,015	1,043	1,094	1,092	1,094	1,111	1,188	1,208	1,227	1,286	1,349	1,346
Gross margin	77%	78%	80%	81%	81%	81%	81%	80%	80%	78%	80%	81%	79%	79%	78%	78%	78%	78%	77%	78%
R&D	233	229	251	234	232	261	244	243	270	257	272	253	271	255	276	281	268	263	279	281
SG&A	424	370	409	377	411	436	410	382	480	428	448	421	492	466	502	515	603	522	561	561
Operating income	374	439	460	402	448	388	264	366	400	349	366	351	313	395	411	307	151	478	513	299
Operating margin	28%	33%	33%	31%	33%	32%	21%	29%	32%	26%	27%	26%	23%	28%	27%	20%	10%	29%	29%	17%
Pre-tax income	376	436	465	407	459	399	275	388	422	371	384	403	390	434	400	348	90.4	459	520	363
Tax rate	11%	14%	13%	16%	13%	15%	8%	14%	12%	12%	5%	10%	12%	16%	16%	16%	29%	17%	54%	17%
Net income	335	374	406	344	398	340	307	385	370	352	366	3,071	386	358	333	291	91.2	381	242	308
Net margin	25%	28%	30%	26%	30%	28%	24%	31%	29%	26%	27%	227%	28%	25%	22%	19%	6%	23%	14%	18%
Diluted EPS	$0.53	$0.59	$0.65	$0.55	$0.65	$0.56	$0.50	$0.63	$0.61	$0.58	$0.61	$5.13	$0.65	$0.61	$0.56	$0.50	$0.16	$0.66	$0.42	$0.53
Operating cash flow	374	293	332	310	283	314	33.6	412	137	-53.5	372	352	-128	280	290	574	451	43.8	652	570
Capital expenditure	89.8	72.7	43.1	59.9	68.9	61.5	47.9	55.3	88.3	65.3	85.4	51.9	49.8	56.0	49.3	57.5	97.4	64.9	66.9	63.6
Free cash flow	284	221	289	250	214	253	-14.3	356	48.3	-119	286	300	-177	224	241	516	354	-21.1	585	507
Buybacks	96.5	406	355	100	866	249	7.5	174	448	0.2	158	901	100	259	5.5	589	40.6	422	153	139
Shares outstanding	624m	621m	620m	619m	608m	606m	608m	606m	601m	602m	602m	590m	589m	586m	588m	581m	581m	577m	577m	576m
Filing	10-K	10-Q	10-Q	10-Q	10-K	10-K	10-K	10-Q	10-K	10-K	10-K	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q

Each quarter as filed, linked to its filing.

* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

10-Q for the period ended 31 March 2022, filed 28 April 2022: the filing.